Omeros EPS beats by $0.09, beats on revenue
- BySeeking Alpha-
Omeros (OMER): Q2 GAAP EPS of -$0.46 beats by $0.09.Revenue of $28.8M (+112.9% Y/Y) beats by $4.53M.At June 30, 2021, Omeros had cash, cash equivalents and short-term...
Symbol | Exchange | Currency |
|---|
Omeros (OMER): Q2 GAAP EPS of -$0.46 beats by $0.09.Revenue of $28.8M (+112.9% Y/Y) beats by $4.53M.At June 30, 2021, Omeros had cash, cash equivalents and short-term...
Omeros Corporation (NASDAQ: OMER) has announced the presentation of data on organ function improvement from its pivotal trial of narsoplimab for the treatment of hematopoietic stem...
Commercial-stage biopharmaceutical Omeros (NASDAQ:OMER) Corporation OMER announced encouraging preliminary results from an early-stage study of its MASP-3 inhibitor, OMS906.The...
Dates and content of the Prescription Drug User Fee Act are essential for portfolio managers of health-care stocks. A single positive or negative announcement from the U.S. Food...
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Strong Buy | Strong Buy | Strong Buy | Strong Buy | Buy |
| Technical Indicators | Strong Buy | Strong Buy | Strong Buy | Sell | Neutral |
| Summary | Strong Buy | Strong Buy | Strong Buy | Neutral | Neutral |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 148.79 | 148.97 | 147.22 | -0.24 | -0.16% | 67.85M | NASDAQ | |||
| 373.06 | 373.56 | 369.71 | -0.86 | -0.23% | 11.57M | NASDAQ | |||
| 2,872.20 | 2,886.00 | 2,848.00 | -16.4 | -0.57% | 1.28M | NASDAQ | |||
| 4.44 | 4.47 | 4.44 | 0.000 | 0.00% | 0.00 | NYSE | |||
| 18.51 | 18.98 | 18.40 | -0.85 | -4.39% | 39.94M | NYSE | |||
| 6.15 | 6.29 | 6.00 | +0.010 | +0.16% | 20.26M | NASDAQ | |||
| 5.58 | 5.75 | 5.45 | -0.290 | -4.94% | 21.00M | NYSE | |||
| 86.47 | 86.82 | 85.40 | -0.03 | -0.03% | 453.98K | NASDAQ | |||
| 44.47 | 44.99 | 44.03 | -0.30 | -0.67% | 22.12M | NYSE | |||
| 1.70 | 1.80 | 1.65 | -0.0800 | -4.49% | 21.16M | NYSE | |||
| 87.25 | 87.97 | 86.19 | -0.48 | -0.55% | 12.34M | NYSE | |||
| 206.37 | 216.55 | 201.15 | +1.85 | +0.90% | 3.04M | NYSE | |||
| 156.26 | 157.64 | 153.67 | -1.60 | -1.01% | 24.29M | NYSE | |||
| 12.11 | 12.36 | 11.81 | -0.68 | -5.32% | 6.21M | NYSE | |||
| 53.83 | 54.89 | 53.42 | -2.12 | -3.79% | 1.78M | NYSE |
Omeros Corporation is a commercial-stage biopharmaceutical company. The Company is engaged in discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, complement-mediated diseases and disorders of the central nervous system. The Company’s drug product OMIDRIA (phenylephrine and ketorolac intraocular solution) is used during cataract surgery or intraocular lens (IOL) replacement. The Company’s clinical-stage development programs are focused on complement-associated thrombotic microangiopathies, complement-mediated glomerulonephropathies, Huntington’s disease and cognitive impairment, and addictive and compulsive disorders. It also offers a diverse group of preclinical programs and platforms that are used to unlock new G protein-coupled receptor (GPCR) drug targets and to generate antibodies.